A detailed history of Knott David M Jr transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Knott David M Jr holds 332,000 shares of AVDL stock, worth $3.4 Million. This represents 1.53% of its overall portfolio holdings.

Number of Shares
332,000
Previous 333,000 0.3%
Holding current value
$3.4 Million
Previous $4.68 Million 7.01%
% of portfolio
1.53%
Previous 1.87%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$12.6 - $16.91 $12,600 - $16,910
-1,000 Reduced 0.3%
332,000 $4.35 Million
Q1 2024

May 14, 2024

BUY
$12.55 - $17.22 $1.02 Million - $1.4 Million
81,150 Added 32.22%
333,000 $5.62 Million
Q4 2023

Feb 13, 2024

BUY
$9.64 - $14.59 $289,200 - $437,700
30,000 Added 13.52%
251,850 $3.56 Million
Q3 2023

Nov 13, 2023

SELL
$10.3 - $15.99 $193,423 - $300,276
-18,779 Reduced 7.8%
221,850 $2.29 Million
Q2 2023

Aug 11, 2023

SELL
$8.48 - $16.48 $428,104 - $831,976
-50,484 Reduced 17.34%
240,629 $3.97 Million
Q1 2023

May 11, 2023

SELL
$6.41 - $9.95 $122,674 - $190,423
-19,138 Reduced 6.17%
291,113 $2.67 Million
Q4 2022

Feb 13, 2023

SELL
$5.02 - $10.0 $404,662 - $806,100
-80,610 Reduced 20.62%
310,251 $2.22 Million
Q3 2022

Nov 10, 2022

BUY
$2.57 - $7.31 $429,398 - $1.22 Million
167,081 Added 74.66%
390,861 $1.96 Million
Q2 2022

Aug 11, 2022

BUY
$1.07 - $6.95 $17,245 - $112,013
16,117 Added 7.76%
223,780 $546,000
Q1 2022

May 16, 2022

SELL
$5.46 - $8.29 $275,921 - $418,935
-50,535 Reduced 19.57%
207,663 $1.42 Million
Q4 2021

Feb 11, 2022

BUY
$7.34 - $11.18 $1.9 Million - $2.89 Million
258,198 New
258,198 $2.09 Million

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $620M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Knott David M Jr Portfolio

Follow Knott David M Jr and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Knott David M Jr, based on Form 13F filings with the SEC.

News

Stay updated on Knott David M Jr with notifications on news.